search
Back to results

Access Program With Denileukin Diftitox for the Treatment of Patients Currently Receiving Treatment With Commercially Available (Ontak)

Primary Purpose

Cancer

Status
No longer available
Phase
Locations
Study Type
Expanded Access
Intervention
Denileukin diftitox (ONTAK)
Sponsored by
Eisai Inc.
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an expanded access trial for Cancer focused on measuring Cancer, ONTAK, Denileukin diftitox, persistent or recurrent disease, requiring continued delivery of essential cancer therapy

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All Sexes

Inclusion Criteria:

To receive denileukin diftitox (ONTAK) under this protocol, the patient's physician must request this therapy for the specific patient. Patients may continue treatment with denileukin diftitox if they:

  • Are currently on therapy with denileukin diftitox and require ongoing therapy to maintain control of their disease.
  • Are willing and able to comply with all aspects of the Access Protocol
  • Provide written informed consent to participate

Exclusion Criteria:

Patients are not eligible for the Access Program with denileukin diftitox if they:

• Are not currently on denileukin diftitox therapy

Sites / Locations

    Outcomes

    Primary Outcome Measures

    Secondary Outcome Measures

    Full Information

    First Posted
    September 7, 2011
    Last Updated
    January 22, 2015
    Sponsor
    Eisai Inc.
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT01432483
    Brief Title
    Access Program With Denileukin Diftitox for the Treatment of Patients Currently Receiving Treatment With Commercially Available (Ontak)
    Official Title
    Access Program With Denileukin Diftitox for the Treatment of Patients Currently Receiving Treatment With Commercially Available (Ontak)
    Study Type
    Expanded Access

    2. Study Status

    Record Verification Date
    January 2015
    Overall Recruitment Status
    No longer available
    Study Start Date
    undefined (undefined)
    Primary Completion Date
    undefined (undefined)
    Study Completion Date
    undefined (undefined)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Eisai Inc.

    4. Oversight

    5. Study Description

    Brief Summary
    The purpose of this study is to provide continued therapy with Denileukin diftitox (ONTAK) to patients who are currently on therapy and who have no other suitable treatment options, where therapy is requested by their physician.
    Detailed Description
    The Access Program will be provided as long as appropriate according to the judgment of the provider. If Denileukin diftitox (ONTAK) becomes commercially available without restriction, then the access program will be discontinued.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Cancer
    Keywords
    Cancer, ONTAK, Denileukin diftitox, persistent or recurrent disease, requiring continued delivery of essential cancer therapy

    7. Study Design

    8. Arms, Groups, and Interventions

    Intervention Type
    Drug
    Intervention Name(s)
    Denileukin diftitox (ONTAK)
    Other Intervention Name(s)
    ONTAK
    Intervention Description
    Given at a dose of 9 or 18mcg/kg/day by intravenous infusion over 30 to 60 minutes for 5 consecutive days every 21 days for 8 cycles.

    10. Eligibility

    Sex
    All
    Eligibility Criteria
    Inclusion Criteria: To receive denileukin diftitox (ONTAK) under this protocol, the patient's physician must request this therapy for the specific patient. Patients may continue treatment with denileukin diftitox if they: Are currently on therapy with denileukin diftitox and require ongoing therapy to maintain control of their disease. Are willing and able to comply with all aspects of the Access Protocol Provide written informed consent to participate Exclusion Criteria: Patients are not eligible for the Access Program with denileukin diftitox if they: • Are not currently on denileukin diftitox therapy
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Gary Palmer, MD
    Organizational Affiliation
    Eisai Inc.
    Official's Role
    Study Director

    12. IPD Sharing Statement

    Learn more about this trial

    Access Program With Denileukin Diftitox for the Treatment of Patients Currently Receiving Treatment With Commercially Available (Ontak)

    We'll reach out to this number within 24 hrs